The FDA has expanded the approved use of ibrutinib (Imbruvica) to include patients with Waldenström macroglobulinemia, a rare type of non-Hodgkin lymphoma.
Hematologic Cancer Targets
In its Annual Report on Progress Against Cancer, ASCO has declared that the transformation in the treatment of patients with CLL is the “advance of the year.”
Long-term follow-up confirmed the previously reported result that intermittent administration of imatinib is safe and effective in CML patients.
Despite the early trial termination due to safety concerns, an analysis suggests that ponatinib offers improved efficacy over imatinib in newly diagnosed CML.
A new trial reported improved overall survival in myeloma patients who received a higher bortezomib dose as part of a bortezomib/melphalan/prednisone regimen.
According to a report, two courses of the newly approved agent blinatumomab, for relapsed or refractory B-cell precursor ALL, will cost a staggering $178,000.
The addition of daratumumab to traditional therapies used in the treatment of multiple myeloma was well tolerated and associated with high rates of responses.
An oral inhibitor of isocitrate dehydrogenase 2 (IDH2), AG-221, has shown activity and potentially durable remissions in patients with acute myeloid leukemia.
Early consolidation therapy with brentuximab vedotin after autologous stem cell transplant improved progression-free survival of patients with Hodgkin lymphoma.
A single cycle of blinatumomab resulted in complete minimal residual disease response in 78% of patients with acute lymphoblastic leukemia.